Pharmaceutical Services Negotiating Committee (PSNC) - News updates


CPCS IT provision: Support for switchover

NHS England and NHS Improvement (NHSE&I) have issued further support for the transfer of the cost of Community Pharmacist Consultation Service (CPCS) IT solutions to pharmacy contractors. Ahead of the switchover coming into effect on 1st April 2022, contractors are encouraged to take action now and plan to sign up to one of four assured...

CPPE launches Newly qualified pharmacist programme

The Centre for Pharmacy Postgraduate Education (CPPE) has launched their Newly qualified pharmacist programme, which is now open for applications. The fully funded 12-month programme is open to pharmacists (including locums) who completed pre-registration training in the 2020/21 cohort and are working in independent or small/medium multiple community pharmacies. Applicants must be on the General...

September 2021 Price Concessions 1st Update

The Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack size Price Concession Baclofen 10mg tablets 84 £2.34 Olmesartan medoxomil 40mg tablets 28 £9.45 Orlistat 120mg capsules 84 £21.45 Pregabalin 50mg capsules 84 £4.05 Sulfasalazine 500mg gastro-resistant tablets 112 £17.15 Trazodone 50mg capsules 84 £3.59...

PQS: Patient safety report resource

A new resource to support community pharmacy contractors to complete their patient safety report, a requirement of the ‘Safety report and demonstrable learnings from the CPPE LASA e-learning’ Gateway criterion of the 2021/22 Pharmacy Quality Scheme (PQS), is now available. PSNC has worked with the Community Pharmacy Patient Safety Group to produce Completing the Patient...

MHRA Class 2 Medicines Recall: Ikervis 1mg/ml eye drops SANTEN Oy (trading as Santen UK Limited)

Class 2 Medicines recall: Ikervis 1 mg/mL eye drops, emulsion Drug alert number: EL (21) A/22 Date issued: 8th September 2021 The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for: Ikervis 1 mg/mL eye drops, emulsion (Santen UK Limited) EU/1/15/990/001  SANTEN Oy (trading as Santen UK Limited) are...

PQS 2021/22 webinar now on-demand

PSNC’s webinar on the Pharmacy Quality Scheme (PQS) for 2021/22 is now available to watch on-demand. Feedback on the PQS webinar “A great intro to this year’s PQS as all the paperwork can be daunting.” “I have confidence now in what our pharmacy needs to do and the information on the PSNC website will be...

MHRA Drug Safety Update September 2021

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 15 Issue 2 September 2021) has been published and includes articles on: Topical corticosteroids: information on the risk of topical steroid withdrawal reactions COVID-19 vaccines: updates for August 2021 Letters and medicine recalls sent to healthcare professionals in August 2021 To see...

PHE publish pharmacy briefing on addressing health inequalities

Public Health England (PHE) has produced a briefing highlighting the unique role that pharmacy teams can play in helping to address health inequalities. The briefing, ‘Pharmacy teams seizing opportunities for addresssing health inequalities’ sets out suggestions on how to make the most of pharmacy teams’ potential to work with local community and faith leaders, reach...

Changes to the C-19 LFD Distribution Service from 4th Oct

Last week there was an announcement of the release of an updated version of the NHS Community Pharmacy COVID-19 Lateral Flow Device (LFD) Distribution Service (Pharmacy Collect) service specification, which will apply from 4th October 2021. The updated service specification follows a review of the service at the end of June 2021 by NHS Test and...

C-19: JCVI issues updated advice on booster vaccination

The Joint Committee on Vaccination and Immunisation (JCVI) has updated its advice on the COVID-19 vaccine booster programme. To maintain the current high level of protection through the coming winter, the JCVI is advising that booster vaccines are offered to those more at risk from serious disease, and who were vaccinated during Phase 1 of the vaccine...